Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | VHL |
Variant | Y112C |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | VHL Y112C lies within the CCT complex-binding region of the Vhl protein (UniProt.org). Y112C has been demonstrated to confer resistance to BET inhibitors in culture (PMID: 36329119), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Jun 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
VHL mutant VHL Y112C |
Transcript | NM_000551.4 |
gDNA | chr3:g.10142182A>G |
cDNA | c.335A>G |
Protein | p.Y112C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354723.2 | chr3:g.10142182A>G | c.335A>G | p.Y112C | RefSeq | GRCh38/hg38 |
NM_198156.2 | chr3:g.10142182A>G | c.335A>G | p.Y112C | RefSeq | GRCh38/hg38 |
NM_000551.4 | chr3:g.10142182A>G | c.335A>G | p.Y112C | RefSeq | GRCh38/hg38 |
NM_001354723.1 | chr3:g.10142182A>G | c.335A>G | p.Y112C | RefSeq | GRCh38/hg38 |
NM_198156.3 | chr3:g.10142182A>G | c.335A>G | p.Y112C | RefSeq | GRCh38/hg38 |
NM_000551.3 | chr3:g.10142182A>G | c.335A>G | p.Y112C | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
VHL Y112C | leukemia | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a leukemia cell line demonstrated resistance to ARV-771 and was found to have acquired VHL Y112C in culture (PMID: 36329119). | 36329119 |
VHL Y112C | colon carcinoma | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a colon carcinoma cell line expressing VHL Y112C was resistant to ARV-771 in culture (PMID: 36329119). | 36329119 |